Dr Reddy's Secures $370M Licensing Deal for Immutep's Cancer Immunotherapy
Key Insights
Dr Reddy's (search) has signed an exclusive licensing agreement with Australia's Immutep worth up to $370 million to develop and distribute eftilagimod alfa, a first-in-class cancer (search) immunotherapy.
The deal grants Dr Reddy's (search) distribution rights for all regions except North America, Europe, Japan and Greater China, with Immutep receiving $20 million upfront and potential milestone payments up to $349.5 million.
Eftilagimod alfa is currently being tested in a Phase III trial for first-line treatment of advanced non-small cell lung cancer (search) in combination with pembrolizumab and chemotherapy.
Indian pharmaceutical giant Dr Reddy's (search) has entered into an exclusive licensing agreement with Australia's Immutep to develop and distribute eftilagimod alfa, a novel cancer (search) immunotherapy, in a deal potentially worth up to $370 million. The partnership marks a significant expansion of Dr Reddy's oncology portfolio as the company continues its strategic shift beyond generic drugs.
Financial Terms and Geographic Scope
Under the licensing agreement announced Monday, Immutep will receive an upfront payment of $20 million from Dr Reddy's (search), along with potential regulatory development and commercial milestone payments of up to $349.5 million. Additionally, Immutep will receive double-digit royalties on commercial sales in the licensed territories.
The deal grants Dr Reddy's (search) exclusive rights to distribute eftilagimod alfa in all regions except North America, Europe, Japan and Greater China. Immutep will retain global manufacturing rights for the drug and will supply it to Dr Reddy's in the licensed regions while maintaining full rights in the key markets of North America, Europe and Japan.
Novel Immunotherapy Mechanism
Eftilagimod alfa represents a first-in-class immunotherapy that directly activates the immune system (search) to fight cancer (search). The drug belongs to a category of treatments that direct the body's immune cells to attack cancer more precisely while reducing side effects compared to traditional chemotherapy approaches.
"This collaboration marks our continuous efforts to deliver first-in-class and innovative therapies for cancer (search) treatment," said M.V. Ramana, CEO – Branded Markets (India & Emerging Markets) at Dr. Reddy's. "Efti is a novel immunotherapy with the potential to set a new standard of care in combination with pembrolizumab (Keytruda) and chemotherapy as first-line therapy for non-small cell lung cancer (search)."
Clinical Development Program
The drug is currently being evaluated in TACTI-004 (KEYNOTE-F91), a Phase III clinical trial testing eftilagimod alfa as first-line treatment for advanced or metastatic non-small cell lung cancer (search). The trial is investigating the combination of eftilagimod alfa with pembrolizumab and chemotherapy, positioning it as a potential new standard of care for this patient population.
Beyond lung cancer (search), eftilagimod alfa is being studied for additional oncology indications, including head and neck cancer (search), breast cancer (search) and soft tissue sarcoma (search), suggesting broad therapeutic potential across multiple tumor types.
Strategic Portfolio Diversification
The licensing deal represents Dr Reddy's (search) continued efforts to diversify its portfolio beyond generic medications into innovative cancer (search) therapies. This strategic shift comes as the company faces ongoing pricing pressures in North America, which represents its largest market.
Over recent years, Dr Reddy's (search) has been actively expanding its oncology portfolio to include novel cancer (search) treatments, positioning the company to compete in higher-value therapeutic areas while reducing dependence on the increasingly competitive generics market.
Following the announcement, Dr Reddy's (search) shares experienced volatility on the BSE Sensex, initially swinging between gains and losses before declining to the day's low of Rs 1,267.50 per share, reflecting investor uncertainty about the deal's immediate financial impact.